期刊文献+

原发性输卵管癌预后因素研究 被引量:2

Analysis of Prognostic Factors in Primary Fallopian Tube Carcinoma
下载PDF
导出
摘要 目的:探讨影响原发性输卵管癌预后的因素。方法:应用单因素和多因素生存分析方法,回顾性分析我院1994年1月至2006年10月收治的有完整临床及随访资料的50例原发性输卵管癌,对其预后因素进行研究。结果:患者平均年龄56岁。总的5年生存率为38%,中位生存时间48个月。单因素分析显示,肿瘤的FIGO分期、分化程度、腹腔细胞学检查结果、术后残留灶大小、淋巴结转移情况、化疗方案均是影响该病预后的因素(均P<0·05)。应用Cox比例风险回归模型显示,FIGO分期、分化程度、术后残留灶大小、淋巴结转移情况是影响该病预后的独立因素(均P<0·05)。结论:原发性输卵管癌预后较差,理想的肿瘤细胞减灭术后辅以紫杉醇、铂类为主的化疗为延长患者生存期提供了一定的可能性。 Objective:To analyze the prognostic factors in primary fallopian tube carcinoma(PFTC).Methods:Fifty patients with PFTC treated at our institution between January,1994 and October,2006 were retrospectively analyzed.All the patients had complete clinical data.Univariate and multivariate stastical methods were used to evaluate several factors for their prognostic impact in this disease.Results:The mean age of the patients was 56 years.The 5-year survival for the group as a whole was 38%,and the median survival was 48 months.In univariate analysis stage,grade,peritoneal cytology,residual disease after surgery,lymph-node metastasis,and chemotherapy regimen were all factors significantly affecting the survival(all P〈0.05).In Cox multiple factor survival analysis stage,grade,residual disease after surgery,and lymph-node metastasis were available independent factors of PFTC(all P〈0.05).Conclusion:The prognosis of PFTC was poor.Aggressive cytoreductive surgery followed by paclitaxel or platinum based chemotherapy offered the possibility of long-term control of PFTC.
出处 《华西医学》 CAS 2008年第3期500-501,共2页 West China Medical Journal
关键词 原发性输卵管癌 预后因素 回归分析 primary fallopian tube carcinoma,prognostic factors,regression analysis
  • 相关文献

参考文献11

  • 1曹泽毅主编.中华妇产科学.第二版.北京:人民卫生出版社,2147-2150.
  • 2Rosenblatt KA, Weiss NS, Schwartz SM. Incidence of malignant fallopian tube tumors [J]. Gynecol Oncol, 1989, 35 (2): 235 - 239.
  • 3Pfeiffer P, Mogensen H, Amtrup F et al. Primary carcinoma of the fallopian tube. A retrospective study of patients reported to the Danish Cancer Registry in a five - year period [J]. Acta Oncol, 1989, 28 (1): 7 -11.
  • 4Vaughan MM, Evans BD, Baranyai J et al. Survival of patients with primary fallopian tube carcinoma [ J]. Int J Gynecol Cancer, 1998, 8 (1): 16-22.
  • 5Ajithkumar TV, Minimole AL, John MM et al. Primary fallopian tube carcinoma [J]. Obstet Gynecol Surv, 2005, 60 (4) : 247 - 252.
  • 6Klein M, Rosen AC, Lahousen Met al. Lymphadenectomy in primary carcinoma of the fallopian tube [ J ]. Cancer Lett, 1999, 147 (1-2): 63-66.
  • 7黄永文,李玉洁,李孟达.Ⅱ~Ⅳ期上皮性卵巢癌术后化疗方案选择和疗程优化的探讨[J].癌症,2005,24(8):994-997. 被引量:9
  • 8McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin com- pared with paclitaxel and cisplatin in patients with stage Ⅲ and stage Ⅳ ovarian cancer [J]. N Engl JMed, 1996, 334 (1): 1-6.
  • 9Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin - paclitaxel versus cisplatincyclophosphamide in women with advanced epithelial ovarian cancer: three - year results [ J ]. J Natl Cancer Inst, 2000, 92 (9): 699-708.
  • 10Muggia FM, Braly PS, Brady MF, et al. Phase Ⅲ randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxeI in patients with suboptimal stage Ⅲ or Ⅳ ovarian cancer: a gynecologic oncology group study [J]. J Clin Oncol, 2000, 18 (1): 106- 15.

二级参考文献5

  • 1李孟达,李玉洁,黄永文,黄鹤.影响上皮性卵巢癌远期疗效的因素分析[J].癌症,2004,23(11):1306-1310. 被引量:19
  • 2李孟达,黄欣.中、晚期卵巢癌综合治疗疗效及影响因素的分析[J].中华妇产科杂志,1996,31(10):621-623. 被引量:35
  • 3李孟达 刘富元 等.顺氯氨铂联合化疗治疗晚期卵巢癌的近期疗效[J].癌症,1983,2(4):269-269.
  • 4Shigemasa K, Gu L, O'Brien TJ, et al. Skp2 overexpression is a prognostic factor in patients with ovarian adenocarcinoma [J].Clin Cancer Res, 2003,9(5): 1756-1763.
  • 5Rose PG, Blessing JA, Mayer AR, et al. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study [J]. J Clin Oncol, 1998,16(2):405-410.

共引文献8

同被引文献20

  • 1郎景和,赵荣国.卵巢癌的淋巴造影[J].中华妇产科杂志,1989,24(1):29-31. 被引量:5
  • 2Klein M,Rosen AC,Lahousen M,et al.Lymphadenectomy in primary carcinoma of the Fallopian tube[J].Cancer Lett,1999,147(1-2):63-66.
  • 3Picart MJ,Bertelsen K,James K,eL al.Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer:three-year results[J].J Natl cancer inst,2000(9):699-708.
  • 4Muggia FM,Braly PS,Brady MF,et al.Phase Ⅲ randomized study of cisplatin and paclitaxel in patients with suboptimal stage Ⅲ or Ⅳ ovarian cancer:a gunecologic oneology group study[J].J Clin Oncol,2000,18(1):106-115.
  • 5曹泽毅.中华妇产科学[M].2版.北京:人民卫生出版社,2004:2163-2169.
  • 6林仲秋.FIGO/IGCS妇科恶性肿瘤分期及临床实践指南(五):输卵管癌[J].国际妇产科杂志,2008,35(5):389-390.
  • 7于爱军,方素华,高永良.输卵管癌治疗效果及影响预后的相关因素分析[J].中华肿瘤杂志,2007,29(10):789-793. 被引量:4
  • 8苏英宽,栾铭箴,汤春生,等.妇产科临床解剖学[M].7版.济南:山东科学技术出版社,2001:424.
  • 9江森.卵巢恶性肿瘤的淋巴结转移及其手术治疗[M]//张振湘.淋巴外科学.北京:人民卫生出版社,1984:320-339.
  • 10Klein M,Rosen AC,Lahousen M,et al.Lymphadenectomy in primary carcinoma of the Fallopian tube[J].Cancer Lrtt,1999,147(1-2):63-66.

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部